68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Launched by THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 68Ga-FAPI-LM3 PET/CT, which targets specific proteins found in certain diseases. The goal is to determine how safe this imaging agent is, how it spreads in the body, and how much radiation it involves. Researchers want to find out if this method is better at detecting tumors in patients with certain conditions compared to a commonly used imaging agent called 18F-FDG.

To participate in this trial, you need to be an adult (18 years or older) with suspected or diagnosed cancer that shows specific markers known as FAP or SSTR2. You should also be scheduled to have both the 68Ga-FAPI-LM3 and 18F-FDG PET/CT scans. Participants can expect to undergo these imaging tests, and those who take part will help researchers learn more about this promising new tool for diagnosing cancer. It's important to know that this study is open to all genders and is currently recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (i) adult patients (aged 18 years or order);
• • (ii) patients with suspected or newly diagnosed or previously malignant disease, with either FAP or SSTR2 positive expression (supporting evidence may include MRI, CT, and pathology report etc);
• • (iii) patients who had scheduled both 18F-FDG and 68Ga-FAPI-LM3 PET/CT scans;
• • (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • (i) patients with non-malignant disease;
• • (ii) patients with pregnancy;
• • (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.